Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 0.23% is 16% below its 2-year average of 0.27%, around the middle of its 2-year range (0.08%–0.49%).
As of the fiscal period ended Tuesday, June 30, 2026. 38.39% below its 12-month average of 0.37%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.23%.
DEBT TO ASSETS RATIO
0.23%
DEBT TO ASSETS RATIO AVG TTM
0.37%
DEBT TO ASSETS RATIO AVG 3Y
N/A
DEBT TO ASSETS RATIO AVG 5Y
N/A
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-38.39%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.12%
median of 391 covered companies
CURRENT VS SECTOR MEDIAN
+89.20%
vs the sector median at left
Bicara Therapeutics Inc. Common Stock
Market Cap
$1.14B
Debt to Assets Ratio
0.23%
TTM Avg
0.37%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.12B
Debt to Assets Ratio
0.07%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.12B
Debt to Assets Ratio
0.39%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.16B
Debt to Assets Ratio
0.23%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.20B
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.05B
Debt to Assets Ratio
0.38%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.24B
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$989.05M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bicara Therapeutics Inc. Common Stock (BCAX) | $1.14B | 0.23% | 0.37% | N/A | N/A |
| Castle Biosciences, Inc. (CSTL)vs › | $1.12B | 0.07% | N/A | N/A | N/A |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.12B | 0.39% | N/A | N/A | N/A |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.16B | 0.23% | N/A | N/A | N/A |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.20B | 0.04% | N/A | N/A | N/A |
| Cronos Group Inc. (CRON)vs › | $1.21B | 0.00% | N/A | N/A | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | 0.38% | N/A | N/A | N/A |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.24B | 0.00% | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $989.05M | 0.02% | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $985.79M | 0.01% | N/A | N/A | N/A |
Debt/Assets
0.2%
Debt/Equity
0.00
Current Ratio
11.59
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 0.23% |
| 2026-03-31 | 0.26% |
| 2025-12-31 | 0.40% |
| 2025-09-30 | 0.47% |
| 2025-06-30 | 0.49% |
| 2025-03-31 | 0.12% |
| 2024-12-31 | 0.13% |
| 2024-09-30 | 0.08% |
| 2024-06-30 | 0.25% |
| 2024-03-31 | 0.25% |
| 2023-12-31 | 0.28% |
